

Chronic Lymphocytic Leukemia- Prognostic Panel

 PATIENT
 REPORT DATE
 BOOKING ID

 Bhanu P Singh
 14 March 2022
 #012202260070

Test Description

Chronic Lymphocytic Leukemia- Prognostic Panel identifies most frequent chromosomal abnormalities in CLL. The panel analyses partial losses of one affected chromosome (del(6q), del(11q), del(13q) or del(17p)) and gains of entire chromosomes (trisomy 12) by interphase fluorescence *in situ* hybridization analysis.

Patient Demographic

Name: Mr Bhanu Pratap Singh

Sex: Male

Date of Birth/Age: 50 years

Disease: Chronic Lymphocytic Leukemia (CLL)

Clinician

Clinician Name: Dr Amit Verma

Medical Facility: Dr AV Institute of Personalized Therapy

and Cancer Research (IPTCR) Pathologist: Not Provided

Specimen

Booking ID: 012202260070 **Sample Type**: Peripheral Blood **Date of Collection**: 26-02-2022 **Date of Booking**: 26-02-2022

RESULT SUMMARY

Chromosome Abnormality	Result
Del6q(MYB)	Negative
Del13q(RB1)	Negative
Del11q(ATM)	Negative
Del17p(TP53)	Negative
Trisomy 12	Negative

INTERPRETATION

- 1. Evaluation of this specimen shows a normal hybridization pattern.
- 2. Del(6q), Del(13q), Del(11q), Del(17p) and Trisomy 12 are not present in any of the interphase cells studied.
- 3. Clinical, hematologic, and molecular correlation is recommended.

COMMENTS

About 80% of the cases have cytogenetic abnormalities detected by FISH. About 50% of CLL show del 13q14.3, about 20% trisomy 12 and, less commonly, deletions of 11q22-23, 17p13 and 6q21.

Jatinder Kaur, PhD

Head, Molecular Biology & Genomics

Dr. Gulshan Yadav, MD

Head, Pathology

Detailed Report

Del6q(MYB)		Result	
Total number of cells scored	200		
Percentage of cells showing Deletion/ Monosomy	0	Negative	
Percentage of cells not showing Deletion/ Monosomy	100	_	2.0
Nomenclature: nuc ish(MYB,CCP6)x2[200]			
Probes used : MYB = Orange, CCP6 = Green			
Cut off for normal individual > 5%			

Comments Interpretation

Presence/Absence of this genetic abnormality carries good/intermediate/poor prognosis.

- 1. Del6q is not present in any of the interphase cells studied.
- 2. Clinical, hematologic, and molecular correlation is recommended.

Del13q(RB1)		Result	
Total number of cells scored	200		
Percentage of cells showing Deletion/ Monosomy	0	Negative	
Percentage of cells not showing Deletion/ Monosomy	100	_	7.0
Nomenclature: nuc ish(D13S319,LAMP1)x2[200]			
Probes used: D13S319 = Orange; LAMP1 = Green			
Cut off for normal individual > 5%			

Comments	Interpretation

1. Del13q is not present in any of the interphase cells studied. Presence/Absence of this genetic abnormality carries good/intermediate/poor prognosis.

2. Clinical, hematologic, and molecular correlation is recommended.

Jatinder Kaur, PhD

Head, Molecular Biology & Genomics

Dr. Gulshan Yadav, MD Head, Pathology



Chronic Lymphocytic Leukemia- Prognostic Panel

PATIENT REPORT DATE BOOKING ID
Bhanu P Singh 14 March 2022 #012202260070

Del11q(ATM), Del17p13.1(TP53)		Result	
Total number of cells scored	200		
Percentage of cells showing Deletion/ Monosomy	0	Negative	•
Percentage of cells not showing Deletion/ Monosomy	100	_	and the second second
Nomenclature: nuc ish(TP53,ATM)x2[200]			1000
Probes used : TP53= Orange; ATM = Green			
Cut off for normal individual > 5%			

Comments	Interpretation
Presence/Absence of this genetic abnormality carries good/intermediate/poor prognosis.	 Del7p(TP53) is not present in any of the interphase cells studied. Del11q(ATM) is not present in any of the interphase cells studied. Clinical, hematologic, and molecular correlation is recommended.

Trisomy 12		Result	
Total number of cells scored	200		
Percentage of cells showing 2 signals	100	Negative	•
Percentage of cells not showing 3 signals	0	_	
Nomenclature: nuc ish(CEP12)x2[200]			•
Probes used : CEP12 Spectrum = Orange			
Cut off for normal individual > 7%			

Comments	Interpretation
	 Trisomy 12 is not present in any of the interphase cells studied. Clinical, hematologic, and molecular correlation is recommended.

Conditions of Reporting

- 1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient named or identified in the bill/test request form.
- 2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory.
- 3. The reported results are for information and are subject to confirmation and interpretation by the referring doctor.
- 4. Some tests are referred to other laboratories to provide a wider test menu to the customer.
- 5. MolQ Laboratory shall in no event be liable for accidental damage, loss, or destruction of specimen, which is not attributable to any direct and mala fide act or omission of MolQ Laboratory or its employees. Liability of MolQ Laboratory for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.

Disclaimer

This test is not FDA approved / cleared for specific uses.

Jatinder Kaur, PhD

Head, Molecular Biology & Genomics

Dr. Gulshan Yadav, MD Head, Pathology